Starting MS Treatment Early May Help Protect Mobility

Credibility

Interest

Share:2 min read

Key Takeaway

In a 10-year study, people who started ocrelizumab earlier were less likely to have lasting disability than those who started it two years later.

What They Found

The study followed people with relapsing MS, a form of MS with periods of new or worsening symptoms. Some started ocrelizumab right away, while others used a different treatment for two years before switching to ocrelizumab. Over 10 years, the early-start group had a 24% lower risk of lasting disability getting worse than the delayed-start group. They were also less likely to reach a level of disability at which people usually need a walking aid. In the early-start group, the average number of relapses fell over time, and rates of serious side effects, including serious infections, did not rise during the eight-year follow-up period.

Who Should Care and Why

People with relapsing MS may find this study useful when talking with their MS care team about when to start treatment. Its main message is that protecting abilities early may be easier than trying to regain them after they are lost. This matters for everyday goals, such as staying mobile and keeping up with work, family, or hobbies. Caregivers can use the findings to help prepare questions about treatment benefits and risks. If you are choosing or reviewing an MS treatment, ask your care team how these results fit your health history and priorities.

Important Considerations

This study included adults ages 18 to 55 with relapsing MS, so the results may not apply in the same way to older adults or people with other forms of MS. Not everyone stayed in the study for all 10 years, which makes long-term results less certain. The study compared starting ocrelizumab right away with starting it after two years on one other treatment; it does not show that ocrelizumab is the best choice for everyone.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Treatment Updates Living with MS

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like JAMA neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News